Page last updated: 2024-10-24
chloral hydrate and Down Syndrome
chloral hydrate has been researched along with Down Syndrome in 1 studies
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Chloral hydrate is a safe and effective agent for sedation of children with known or suspected congenital heart disease who are undergoing echocardiography in the outpatient cardiology clinic." | 1.29 | Safety and efficacy of chloral hydrate sedation in children undergoing echocardiography. ( Ingall, CG; Martin, GR; Napoli, KL, 1996) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Napoli, KL | 1 |
| Ingall, CG | 1 |
| Martin, GR | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Effect of Increasing Depth of Dexmedetomidine and Propofol Anesthesia on Upper Airway Morphology in Children With History of Obstructive Sleep Apnea[NCT01344759] | Phase 4 | 60 participants (Actual) | Interventional | 2009-06-30 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Needed Artificial Airway
This is the count of the number of patients who needed an artificial airway. (NCT01344759)
Timeframe: During MRI and until recovery room discharge - approximately 30-250 minutes
| Intervention | Number of artifical airway events (Number) |
|---|
| Mild OSA and Dexmedetomidine | 0 |
| Mild OSA and Propofol | 1 |
| Moderate OSA and Dexmedetomidine | 1 |
| Moderate OSA and Propofol | 1 |
| Severe OSA and Dexmedetomidine | 2 |
| Severe OSA and Propofol | 5 |
Obstructive Index Until Recovery Room Discharge
The Obstructive Index is a count of the obstructive apnea events per hour of sleep (NCT01344759)
Timeframe: During MRI and until recovery room discharge - approximately 30-250 minutes
| Intervention | Apnea events/hour of sleep (Mean) |
|---|
| Mild OSA and Dexmedetomidine | 4.2 |
| Mild OSA and Propofol | 3.0 |
| Moderate OSA and Dexmedetomidine | 8.0 |
| Moderate OSA and Propofol | 8.0 |
| Severe OSA and Dexmedetomidine | 16.7 |
| Severe OSA and Propofol | 17.1 |
Respiratory Disturbance Index
The respiratory disturbance index is a count of respiratory disturbance events per hour of sleep. (NCT01344759)
Timeframe: During MRI and until recovery room discharge - approximately 30-250 minutes
| Intervention | respir.disturbance events/hr of sleep (Mean) |
|---|
| Mild OSA and Dexmedetomidine | 5.1 |
| Mild OSA and Propofol | 3.2 |
| Moderate OSA and Dexmedetomidine | 8.8 |
| Moderate OSA and Propofol | 7.1 |
| Severe OSA and Dexmedetomidine | 16.6 |
| Severe OSA and Propofol | 25.2 |
Room Air SpO2
The patient's oxygen saturation on room air. (NCT01344759)
Timeframe: During MRI and until recovery room discharge - approximately 30-250 minutes
| Intervention | percentage of SpO2 (Mean) |
|---|
| Mild OSA and Dexmedetomidine | 87.2 |
| Mild OSA and Propofol | 88.0 |
| Moderate OSA and Dexmedetomidine | 86.3 |
| Moderate OSA and Propofol | 89.0 |
| Severe OSA and Dexmedetomidine | 84.0 |
| Severe OSA and Propofol | 88.0 |
Cross Sectional Area of the Pharyngeal Airway
The primary outcome measures will be the cross sectional area of the pharyngeal airway of the patients measured at two levels soft palate (nasopharyngeal) and base of the tongue (retroglossal). Magnetic resonance images of the airway were obtained during low (1 mcg/kg/hr) and high (3 mcg/kg/hr) doses of DEX or low (100 mcg/kg/m) and high (200 mcg/kg/m) doses of Propofol. All were administered through an intravenous (IV) catheter. (NCT01344759)
Timeframe: during MRI within first 10 minutes of scanning
| Intervention | mm^2 (Median) |
|---|
| Low Dose Sedative, Nasopharyngeal measurement | High Dose Sedative, Nasopharyngeal measurement | Low Dose Sedative, Retroglossal measurement | High dose sedative, Retroglossal measurement |
|---|
| Dexmedetomidine | 178.5 | 235.4 | 120.9 | 120.5 |
,| Propofol | 239.9 | 201.6 | 115.1 | 108.1 |
Other Studies
1 other study available for chloral hydrate and Down Syndrome